Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer

Objective: Pembrolizumab plus chemotherapy is recommended as the first-line treatment for advanced oesophageal cancer. The objective of this study is to evaluate the cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer from the healthcare system...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Meiyu, Qin, Shuxia, Wang, Liting, Tan, Chongqing, Peng, Ye, Zeng, Xiaohui, Luo, Xia, Yi, Lidan, Wan, Xiaomin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197184/
https://www.ncbi.nlm.nih.gov/pubmed/35712723
http://dx.doi.org/10.3389/fphar.2022.881787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197184/
https://www.ncbi.nlm.nih.gov/pubmed/35712723
http://dx.doi.org/10.3389/fphar.2022.881787

Ejemplares similares